Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Jnana Therapeutics, Inc.

Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Participate in Upcoming Investor Conferences
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Participate in Upcoming Investor Conferences
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Participate in Upcoming Investor Conferences
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics to Present at the Jefferies Healthcare Conference
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
From Jnana Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.